NCT07528898 2026-04-14
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
Clinical Trials
9 trialsNCT07378306 2026-01-30
FACT-TN
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07372079 2026-01-28
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07187752 2025-09-23
Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes
Shandong Cancer Hospital and Institute
Phase NA Not yet recruiting
NCT07161791 2025-09-09
Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer
Harbin Medical University
Phase 1/2 Not yet recruiting
NCT07005557 2025-06-05
SENIOR
Fudan University
Phase 3 Not yet recruiting
NCT06438055 2024-05-31
Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results
Tianjin Medical University Cancer Institute and Hospital
Phase NA Not yet recruiting
NCT05862610 2023-07-24
The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT04736589 2021-02-03
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
Peking Union Medical College
Phase 3 Not yet recruiting